Replies to post #114713 on Biotech Values

[jq1234]

Because Peter said T-DM1 data weren't spectacular, wasn't stopped early for efficacy. I don't think you can stop single arm trial for efficacy for regulatory approval. I want to be safe by asking first. T-DM1 trial was single arm trial in 3rd line mBC.